Britain and America have agreed to a major bilateral deal that will maintain zero levies on British medicine products entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase spending on medicines through the NHS. This move ensures that duties on these crucial products will be held at nothing for a period of the next three years.
This agreement is in response to recent statements to dramatically increase tariffs on branded pharmaceutical products, with increases mentioned as high as one hundred percent.
"This agreement between the Britain reinforces the international landscape for cutting-edge drugs and brings long-overdue balance to transatlantic pharmaceutical trade," a statement declared.
Economic Impact
Medicines constitute one of the the United Kingdom's biggest export categories to the United States, which is easily the biggest destination for major British pharmaceutical firms.
Trade data show that in the one-year period prior to the third quarter, the UK sold medicines totaling over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that period.
"This deal safeguards employment, increases funding and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key British Pledges
The pact includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at fifteen percent. Previously, refunds were more than 20%.
Industry Background
This agreement takes place against a ongoing tension between the drug companies and the British authorities over medicine costs and regulatory access.
This friction were exacerbated by claims that US customers were charged significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
